\-\ Texto\\:\\ \ \(0\)\
\-\ firm\\,\\ tender\\ mass\\ of\\ the\\ posterior\\ right\\ knee\\.\ \(0\)\
\-\ normal\\ cbc\\,\\ metabolic\\ panel\\,\\ and\\ liver\\ enzymes\\.\ \(0\)\
\-\ mass\\ was\\ surgically\\ resected\\ with\\ no\\ further\\ evidence\\ of\\ metastasis\\ on\\ follow\\-up\\ studies\\.\ \(0\)\
\-\ radiographs\\:\\ \\ large\\ mass\\ with\\ well\\ defined\\ margins\\ emanating\\ from\\ posterior\\ cortex\\ of\\ the\\ distal\\ right\\ femur\\.\\ \\ radiolucent\\ line\\,\\ visible\\ on\\ the\\ lateral\\ radiograph\\ separates\\ tumor\\ from\\ cortex\\ \\.\ \(0\)\
\-\ mri\\:\\ \\ posterior\\ cortical\\ surface\\ distal\\ femoral\\ diaphysis\\ mass\\,\\ 7\\.3cm\\ x\\ 6\\.7cm\\ x\\ 8\\.3cm\\,\\ with\\ heterogeneous\\ signal\\ intensity\\.\\ \\ on\\ t1\\-weighted\\ mr\\ image\\ shows\\ a\\ heterogenously\\ low\\ signal\\ intensity\\ mass\\ signal\\.\\ t2\\-weighted\\ mr\\ image\\ shows\\ a\\ well\\-defined\\ parosteal\\ mass\\ juxtaposed\\ to\\ the\\ cortex\\ with\\ heterogenous\\ high\\ signal\\ intensity\\ mass\\ posterior\\ to\\ it\\.\\ \\ t2\\ post\\ gadolinium\\ study\\ shows\\ low\\ signal\\ intensity\\ in\\ posterior\\ mass\\ correlating\\ with\\ high\\ signal\\ intensity\\ region\\ on\\ t2\\ image\\ consistent\\ with\\ necrosis\\.\\ \\ ossification\\ center\\ at\\ base\\ of\\ mass\\ adjacent\\ to\\ cortical\\ bone\\.\\ \\ no\\ popliteal\\ vessel\\ invasion\\,\\ no\\ adjacent\\ soft\\ tissue\\ invasion\\.\\ \\ no\\ femoral\\ distant\\ metastasis\\.\ \(0\)\
\-\ parosteal\\ osteosarcoma\ \(9\)\
\-\ parosteal\\ osteosarcoma\\,\\ juxtacortical\\ \\ myositis\\ ossificans\\,\\ sessile\\ osteochondroma\\,\\ periosteal\\ osteosarcoma\ \(0\)\
\-\ 24\\ y\\/o\\ male\\ with\\ right\\ posterior\\ knee\\ mass\ \(1\)\
\-\ parosteal\\ osteosarcomas\\ are\\ uncommon\\ malignant\\ bone\\ tumors\\ that\\ account\\ for\\ approximately\\ 3\\%\\ of\\ osteosarcomas\\.\\ \\ they\\ occur\\ in\\ adults\\ between\\ the\\ 2nd\\ and\\ 5th\\ decades\\ and\\ affect\\ both\\ males\\ and\\ females\\ equally\\.\\ \\ they\\ typically\\ present\\ with\\ insidious\\ onset\\ of\\ symptoms\\ of\\ pain\\,\\ swelling\\,\\ and\\ a\\ palpable\\ mass\\.\\ \\ the\\ large\\ size\\ of\\ many\\ of\\ these\\ tumors\\ on\\ presentation\\ is\\ due\\ to\\ a\\ delay\\ in\\ the\\ patient\\ consulting\\ a\\ physician\\ because\\ of\\ the\\ slow\\ onset\\ of\\ symptoms\\.\\ \\ parosteal\\ osteosarcomas\\ occur\\ nearly\\ exclusively\\ in\\ long\\ tubular\\ bones\\,\\ most\\ commonly\\ in\\ the\\ femur\\,\\ which\\ accounts\\ for\\ 65\\%\\ of\\ cases\\.\\ \\ in\\ this\\ bone\\,\\ they\\ typically\\ arise\\ on\\ the\\ posterior\\ surface\\ of\\ the\\ distal\\ femur\\ in\\ the\\ metaphyseal\\ region\\.\ \(0\)\
\-\ on\\ plain\\ radiographs\\,\\ parosteal\\ osteosarcomas\\ appear\\ as\\ a\\ large\\ radiodense\\,\\ oval\\ or\\ spheroid\\ mass\\ with\\ smooth\\ lobulated\\ or\\ irregular\\ margins\\,\\ attached\\ in\\ a\\ sessile\\ manner\\ to\\ a\\ possibly\\ thickened\\ external\\ cortex\\.\\ \\ a\\ thin\\ radiolucent\\ line\\ or\\ cleavage\\ plane\\ separates\\ the\\ tumor\\ from\\ the\\ underlying\\ bone\\ and\\ is\\ caused\\ by\\ a\\ 2\\-3mm\\ fibrous\\ membrane\\.\\ \\ as\\ the\\ lesion\\ grows\\ in\\ size\\,\\ the\\ radiolucent\\ line\\ is\\ obscured\\ by\\ the\\ tumor\\ growing\\ circumferentially\\ around\\ the\\ bone\\.\ \(0\)\
\-\ ossification\\ of\\ the\\ tumor\\ extends\\ from\\ the\\ base\\ of\\ the\\ lesion\\ to\\ its\\ periphery\\ in\\ contrast\\ to\\ myositis\\ ossificans\\,\\ which\\,\\ when\\ mature\\,\\ shows\\ a\\ zonal\\ pattern\\ with\\ peripheral\\ ossification\\.\ \(0\)\
\-\ on\\ ct\\ images\\,\\ foci\\ of\\ radiolucencies\\ in\\ the\\ superficial\\ parts\\ of\\ the\\ tumor\\ may\\ represent\\ low\\-grade\\ malignant\\ cartilaginous\\,\\ fibrous\\ tissue\\,\\ or\\ entrapped\\ fat\\ and\\ trabeculae\\,\\ whereas\\,\\ more\\ central\\ radiolucencies\\ may\\ correlate\\ with\\ high\\-grade\\ dedifferentiated\\ tumor\\.\ \(0\)\
\-\ mri\\ should\\ be\\ done\\ to\\ evaluate\\ the\\ extent\\ of\\ the\\ tumor\\.\\ \ \(0\)\
\-\ at\\ imaging\\ studies\\,\\ parosteal\\ sarcoma\\ \\ should\\ be\\ differentiated\\ from\\ myositis\\ ossificans\\,\\ sessile\\ osteochondroma\\,\\ periosteal\\ osteosarcoma\\,\\ and\\ ossifying\\ soft\\ tissue\\ tumors\\ arising\\ from\\ the\\ cortical\\ bone\\ surface\\.\ \(0\)\
\-\ myositis\\ ossificans\\ may\\ present\\ with\\ a\\ history\\ of\\ trauma\\ followed\\ by\\ rapid\\ development\\ of\\ a\\ soft\\ tissue\\ mass\\,\\ which\\ ossifies\\ at\\ the\\ periphery\\ initially\\ as\\ opposed\\ to\\ the\\ base\\.\ \(0\)\
\-\ sessile\\ osteochondroma\\ should\\ show\\ a\\ continuity\\ between\\ both\\ the\\ cortex\\ and\\ spongiosa\\ of\\ the\\ underlying\\ normal\\ bone\\.\\ \\ \ \(0\)\
\-\ periosteal\\ osteosarcoma\\ is\\ smaller\\ and\\ has\\ a\\ distinctive\\ spiculated\\ periosteal\\ reaction\\.\\ \\ \ \(0\)\
\-\ other\\ ossifying\\ masses\\ from\\ the\\ cortex\\ such\\ as\\ chondrosarcomas\\,\\ high\\-grade\\ osteosarcomas\\ and\\ osteoma\\ should\\ be\\ differentiated\\ by\\ their\\ combined\\ imaging\\,\\ clinical\\ and\\ histologic\\ findings\\.\\ \\ \ \(0\)\
\-\ the\\ treatment\\ of\\ parosteal\\ sarcoma\\ is\\ surgical\\ resection\\ without\\ adjuvant\\ chemotherapy\\.\ \(0\)\
\-\ parosteal\\ osteosarcomas\\ are\\ uncommon\\ malignant\\ bone\\ tumors\\ that\\ account\\ for\\ approximately\\ 3\\%\\ of\\ osteosarcomas\\.\\ \\ they\\ occur\\ in\\ adults\\ between\\ the\\ 2nd\\ and\\ 5th\\ decades\\ and\\ affect\\ both\\ males\\ and\\ females\\ equally\\.\\ \\ they\\ typically\\ present\\ with\\ insidious\\ onset\\ of\\ symptoms\\ of\\ pain\\,\\ swelling\\,\\ and\\ a\\ palpable\\ mass\\.\\ \\ the\\ large\\ size\\ of\\ many\\ of\\ these\\ tumors\\ on\\ presentation\\ is\\ due\\ to\\ a\\ delay\\ in\\ the\\ patient\\ consulting\\ a\\ physician\\ because\\ of\\ the\\ slow\\ onset\\ of\\ symptoms\\.\\ \\ parosteal\\ osteosarcomas\\ occur\\ nearly\\ exclusively\\ in\\ long\\ tubular\\ bones\\,\\ most\\ commonly\\ in\\ the\\ femur\\,\\ which\\ accounts\\ for\\ 65\\%\\ of\\ cases\\.\\ \\ in\\ this\\ bone\\,\\ they\\ typically\\ arise\\ on\\ the\\ posterior\\ surface\\ of\\ the\\ distal\\ femur\\ in\\ the\\ metaphyseal\\ region\\.\ \(0\)\
\-\ on\\ plain\\ radiographs\\,\\ parosteal\\ osteosarcomas\\ appear\\ as\\ a\\ large\\ radiodense\\,\\ oval\\ or\\ spheroid\\ mass\\ with\\ smooth\\ lobulated\\ or\\ irregular\\ margins\\,\\ attached\\ in\\ a\\ sessile\\ manner\\ to\\ a\\ possibly\\ thickened\\ external\\ cortex\\.\\ \\ a\\ thin\\ radiolucent\\ line\\ or\\ cleavage\\ plane\\ separates\\ the\\ tumor\\ from\\ the\\ underlying\\ bone\\ and\\ is\\ caused\\ by\\ a\\ 2\\-3mm\\ fibrous\\ membrane\\.\\ \\ as\\ the\\ lesion\\ grows\\ in\\ size\\,\\ the\\ radiolucent\\ line\\ is\\ obscured\\ by\\ the\\ tumor\\ growing\\ circumferentially\\ around\\ the\\ bone\\.\ \(0\)\
\-\ ossification\\ of\\ the\\ tumor\\ extends\\ from\\ the\\ base\\ of\\ the\\ lesion\\ to\\ its\\ periphery\\ in\\ contrast\\ to\\ myositis\\ ossificans\\,\\ which\\,\\ when\\ mature\\,\\ shows\\ a\\ zonal\\ pattern\\ with\\ peripheral\\ ossification\\.\ \(0\)\
\-\ on\\ ct\\ images\\,\\ foci\\ of\\ radiolucencies\\ in\\ the\\ superficial\\ parts\\ of\\ the\\ tumor\\ may\\ represent\\ low\\-grade\\ malignant\\ cartilaginous\\,\\ fibrous\\ tissue\\,\\ or\\ entrapped\\ fat\\ and\\ trabeculae\\,\\ whereas\\,\\ more\\ central\\ radiolucencies\\ may\\ correlate\\ with\\ high\\-grade\\ dedifferentiated\\ tumor\\.\ \(0\)\
\-\ mri\\ should\\ be\\ done\\ to\\ evaluate\\ the\\ extent\\ of\\ the\\ tumor\\.\\ \ \(0\)\
\-\ at\\ imaging\\ studies\\,\\ parosteal\\ sarcoma\\ \\ should\\ be\\ differentiated\\ from\\ myositis\\ ossificans\\,\\ sessile\\ osteochondroma\\,\\ periosteal\\ osteosarcoma\\,\\ and\\ ossifying\\ soft\\ tissue\\ tumors\\ arising\\ from\\ the\\ cortical\\ bone\\ surface\\.\ \(0\)\
\-\ myositis\\ ossificans\\ may\\ present\\ with\\ a\\ history\\ of\\ trauma\\ followed\\ by\\ rapid\\ development\\ of\\ a\\ soft\\ tissue\\ mass\\,\\ which\\ ossifies\\ at\\ the\\ periphery\\ initially\\ as\\ opposed\\ to\\ the\\ base\\.\ \(0\)\
\-\ sessile\\ osteochondroma\\ should\\ show\\ a\\ continuity\\ between\\ both\\ the\\ cortex\\ and\\ spongiosa\\ of\\ the\\ underlying\\ normal\\ bone\\.\\ \\ \ \(0\)\
\-\ periosteal\\ osteosarcoma\\ is\\ smaller\\ and\\ has\\ a\\ distinctive\\ spiculated\\ periosteal\\ reaction\\.\\ \\ \ \(0\)\
\-\ other\\ ossifying\\ masses\\ from\\ the\\ cortex\\ such\\ as\\ chondrosarcomas\\,\\ high\\-grade\\ osteosarcomas\\ and\\ osteoma\\ should\\ be\\ differentiated\\ by\\ their\\ combined\\ imaging\\,\\ clinical\\ and\\ histologic\\ findings\\.\\ \\ \ \(0\)\
\-\ the\\ treatment\\ of\\ parosteal\\ sarcoma\\ is\\ surgical\\ resection\\ without\\ adjuvant\\ chemotherapy\\.\ \(0\)\
\-\ the\\ major\\ prognostic\\ factors\\ are\\ the\\ grade\\ of\\ the\\ lesion\\ and\\ presence\\ of\\ intramedullary\\ involvement\\.\\ \\ low\\-grade\\ lesions\\ have\\ a\\ better\\ prognosis\\ than\\ high\\-grade\\ lesions\\.\\ \\ intramedulary\\ invasion\\ has\\ a\\ poor\\ prognosis\\.\\ \\ it\\ is\\ extremely\\ rare\\ for\\ distant\\ metastasis\\ to\\ occur\\ without\\ intramedulary\\ involvement\\.\ \(0\)\
\-\ another\\ poor\\ prognostic\\ factor\\ is\\ progressive\\ dedifferentiation\\ from\\ low\\-grade\\ to\\ high\\-grade\\ osteosarcoma\\.\\ \\ this\\ has\\ been\\ reported\\ to\\ develop\\ with\\ recurrence\\ after\\ surgical\\ resection\\ or\\ with\\ undetected\\ conventional\\ parosteal\\ osteosarcoma\\ over\\ a\\ long\\ period\\ of\\ time\\.\\ \\ the\\ incidence\\ of\\ dedifferentiation\\ of\\ parosteal\\ osteosarcomas\\ is\\ reported\\ can\\ be\\ as\\ frequent\\ as\\ 20\\-25\\%\\ of\\ patients\\.\\ \\ the\\ posterior\\ aspect\\ of\\ the\\ femur\\ is\\ the\\ usual\\ site\\ for\\ dedifferentiated\\ osteosarcoma\\.\ \(0\)\
\-\ as\\ mentioned\\ earlier\\,\\ parosteal\\ osteosarcoma\\ is\\ the\\ most\\ favorable\\ osteosarcoma\\ variant\\.\\ \\ patients\\ with\\ conventional\\ parosteal\\ osteosarcoma\\ typically\\ do\\ well\\ after\\ resection\\ with\\ a\\ long\\-term\\ survival\\ rate\\ of\\ 80\\-90\\%\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ parosteal\\:\\ 0\\.3825226857860264\ \(0\)\
\-\ osteosarcomas\\:\\ 0\\.3176813890360204\ \(0\)\
\-\ the\\:\\ 0\\.24503165035567845\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.22210895381067208\ \(0\)\
\-\ of\\:\\ 0\\.16963432699728254\ \(0\)\
\-\ sessile\\:\\ 0\\.15473564571379436\ \(0\)\
\-\ ossificans\\:\\ 0\\.1480369077953535\ \(0\)\
\-\ grade\\:\\ 0\\.14284519494904\ \(0\)\
\-\ myositis\\:\\ 0\\.14071854029038044\ \(0\)\
\-\ cortex\\:\\ 0\\.1323517237991076\ \(0\)\
\-\ bone\\:\\ 0\\.12809554404736526\ \(0\)\
\-\ tumor\\:\\ 0\\.12279614051793916\ \(0\)\
\-\ periosteal\\:\\ 0\\.11124367668390019\ \(0\)\
\-\ radiolucencies\\:\\ 0\\.11038600982018199\ \(0\)\
\-\ mass\\:\\ 0\\.1103683359334406\ \(0\)\
\-\ radiolucent\\:\\ 0\\.09864885193385685\ \(0\)\
\-\ osteochondroma\\:\\ 0\\.09547242960167455\ \(0\)\
\-\ in\\:\\ 0\\.09434187781286725\ \(0\)\
\-\ should\\:\\ 0\\.09426749376043435\ \(0\)\
\-\ from\\:\\ 0\\.0932390273740567\ \(0\)\
\-\ and\\:\\ 0\\.08955965679190422\ \(0\)\
\-\ femur\\:\\ 0\\.0888933289920674\ \(0\)\
\-\ ossifying\\:\\ 0\\.08701189390341972\ \(0\)\
\-\ posterior\\:\\ 0\\.08404575656914262\ \(0\)\
\-\ ossification\\:\\ 0\\.08396995084596819\ \(0\)\
\-\ high\\:\\ 0\\.08210800324259364\ \(0\)\
\-\ to\\:\\ 0\\.08126445015208748\ \(0\)\
\-\ as\\:\\ 0\\.07980394949242453\ \(0\)\
\-\ tumors\\:\\ 0\\.07968838570065824\ \(0\)\
\-\ dedifferentiated\\:\\ 0\\.07793798308419149\ \(0\)\
\-\ they\\:\\ 0\\.07742055344865728\ \(0\)\
\-\ surface\\:\\ 0\\.07533701510373254\ \(0\)\
\-\ with\\:\\ 0\\.07425936151691828\ \(0\)\
\-\ is\\:\\ 0\\.07418332215804976\ \(0\)\
\-\ separates\\:\\ 0\\.07347416233337001\ \(0\)\
\-\ periphery\\:\\ 0\\.07287968543155766\ \(0\)\
\-\ line\\:\\ 0\\.0703604913756373\ \(0\)\
\-\ differentiated\\:\\ 0\\.06896668805695422\ \(0\)\
\-\ base\\:\\ 0\\.0686853760512434\ \(0\)\
\-\ occur\\:\\ 0\\.06640698808388187\ \(0\)\
\-\ tissue\\:\\ 0\\.06631307483882078\ \(0\)\
\-\ on\\:\\ 0\\.0654492044553242\ \(0\)\
\-\ intensity\\:\\ 0\\.06411509916883829\ \(0\)\
\-\ typically\\:\\ 0\\.06338775700744001\ \(0\)\
\-\ low\\:\\ 0\\.06217379717179922\ \(0\)\
\-\ signal\\:\\ 0\\.06142249106497699\ \(0\)\
\-\ by\\:\\ 0\\.06135087966594924\ \(0\)\
\-\ sarcoma\\:\\ 0\\.06059642308547948\ \(0\)\
\-\ underlying\\:\\ 0\\.058967712484641874\ \(0\)\
\-\ dedifferentiation\\:\\ 0\\.0577602525520037\ \(0\)\
\-\ or\\:\\ 0\\.056541354621180276\ \(0\)\
\-\ fibrous\\:\\ 0\\.05611291837359963\ \(0\)\
\-\ spheroid\\:\\ 0\\.05519300491009099\ \(0\)\
\-\ spongiosa\\:\\ 0\\.05519300491009099\ \(0\)\
\-\ may\\:\\ 0\\.054526873433443805\ \(0\)\
\-\ zonal\\:\\ 0\\.05337151372045852\ \(0\)\
\-\ entrapped\\:\\ 0\\.05337151372045852\ \(0\)\
\-\ intramedulary\\:\\ 0\\.05337151372045852\ \(0\)\
\-\ shows\\:\\ 0\\.052995085366617366\ \(0\)\
\-\ cleavage\\:\\ 0\\.051958655389461\ \(0\)\
\-\ ossifies\\:\\ 0\\.051958655389461\ \(0\)\
\-\ cortical\\:\\ 0\\.05186039627280777\ \(0\)\
\-\ malignant\\:\\ 0\\.05149213441989568\ \(0\)\
\-\ be\\:\\ 0\\.05128044082213394\ \(0\)\
\-\ consulting\\:\\ 0\\.04982824382318519\ \(0\)\
\-\ chondrosarcomas\\:\\ 0\\.04982824382318519\ \(0\)\
\-\ which\\:\\ 0\\.04926939248948964\ \(0\)\
\-\ size\\:\\ 0\\.048910731898617194\ \(0\)\
\-\ invasion\\:\\ 0\\.04832551069966476\ \(0\)\
\-\ circumferentially\\:\\ 0\\.0482370184366331\ \(0\)\
\-\ distinctive\\:\\ 0\\.0482370184366331\ \(0\)\
\-\ soft\\:\\ 0\\.04807089322004261\ \(0\)\
\-\ long\\:\\ 0\\.04789966356949487\ \(0\)\
\-\ radiodense\\:\\ 0\\.047569916557915815\ \(0\)\
\-\ between\\:\\ 0\\.04693521523382428\ \(0\)\
\-\ onset\\:\\ 0\\.04638455354258045\ \(0\)\
\-\ resection\\:\\ 0\\.04630398132910821\ \(0\)\
\-\ margins\\:\\ 0\\.04622304768519809\ \(0\)\
\-\ grows\\:\\ 0\\.04590872789875097\ \(0\)\
\-\ large\\:\\ 0\\.045242048233092594\ \(0\)\
\-\ parts\\:\\ 0\\.04350594695170986\ \(0\)\
\-\ trabeculae\\:\\ 0\\.04350594695170986\ \(0\)\
\-\ lesion\\:\\ 0\\.04328921255658478\ \(0\)\
\-\ insidious\\:\\ 0\\.04318117772637064\ \(0\)\
\-\ obscured\\:\\ 0\\.04318117772637064\ \(0\)\
\-\ exclusively\\:\\ 0\\.04287225734972729\ \(0\)\
\-\ manner\\:\\ 0\\.04287225734972729\ \(0\)\
\-\ prognostic\\:\\ 0\\.042296259370101\ \(0\)\
\-\ equally\\:\\ 0\\.04202678841545545\ \(0\)\
\-\ adjuvant\\:\\ 0\\.04202678841545545\ \(0\)\
\-\ distal\\:\\ 0\\.04197069865645684\ \(0\)\
\-\ opposed\\:\\ 0\\.04105076616009483\ \(0\)\
\-\ decades\\:\\ 0\\.040828581547324015\ \(0\)\
\-\ cartilaginous\\:\\ 0\\.040828581547324015\ \(0\)\
\-\ histologic\\:\\ 0\\.04040631765705615\ \(0\)\
\-\ both\\:\\ 0\\.0402821377421193\ \(0\)\
\-\ accounts\\:\\ 0\\.040205297225822986\ \(0\)\
\-\ correlate\\:\\ 0\\.03982144565811035\ \(0\)\
\-\ studies\\:\\ 0\\.03974151706521054\ \(0\)\
\-\ metastasis\\:\\ 0\\.03970753700169263\ \(0\)\
\-\ symptoms\\:\\ 0\\.03952324721184107\ \(0\)\
\-\ continuity\\:\\ 0\\.03911720812016468\ \(0\)\
\-\ spiculated\\:\\ 0\\.03911720812016468\ \(0\)\
\-\ oval\\:\\ 0\\.038792438894825455\ \(0\)\
\-\ mature\\:\\ 0\\.03863609485885878\ \(0\)\
\-\ attached\\:\\ 0\\.038334532544342804\ \(0\)\
\-\ whereas\\:\\ 0\\.038334532544342804\ \(0\)\
\-\ osteoma\\:\\ 0\\.03818897184066982\ \(0\)\
\-\ imaging\\:\\ 0\\.03796227048254356\ \(0\)\
\-\ metaphyseal\\:\\ 0\\.037907520538555825\ \(0\)\
\-\ membrane\\:\\ 0\\.037907520538555825\ \(0\)\
\-\ distant\\:\\ 0\\.03777135159692328\ \(0\)\
\-\ affect\\:\\ 0\\.03737958056382793\ \(0\)\
\-\ males\\:\\ 0\\.037254198016197636\ \(0\)\
\-\ present\\:\\ 0\\.03706645014285842\ \(0\)\
\-\ conventional\\:\\ 0\\.036892293131630026\ \(0\)\
\-\ account\\:\\ 0\\.0367761135096723\ \(0\)\
\-\ plane\\:\\ 0\\.03643984271577883\ \(0\)\
\-\ females\\:\\ 0\\.03633160740069522\ \(0\)\
\-\ nearly\\:\\ 0\\.036017578825510974\ \(0\)\
\-\ combined\\:\\ 0\\.0358165583942778\ \(0\)\
\-\ growing\\:\\ 0\\.03543270682656517\ \(0\)\
\-\ radiographs\\:\\ 0\\.035138305428261525\ \(0\)\
\-\ superficial\\:\\ 0\\.0348973222751442\ \(0\)\
\-\ slow\\:\\ 0\\.03481233292191521\ \(0\)\
\-\ image\\:\\ 0\\.034648007270534506\ \(0\)\
\-\ at\\:\\ 0\\.0341053919767227\ \(0\)\
\-\ possibly\\:\\ 0\\.03394579371279763\ \(0\)\
\-\ adults\\:\\ 0\\.03372868861233136\ \(0\)\
\-\ 5th\\:\\ 0\\.03358798033838727\ \(0\)\
\-\ rapid\\:\\ 0\\.03358798033838727\ \(0\)\
\-\ lobulated\\:\\ 0\\.03331561095762197\ \(0\)\
\-\ delay\\:\\ 0\\.033118757431276305\ \(0\)\
\-\ 2nd\\:\\ 0\\.033054476556844396\ \(0\)\
\-\ arise\\:\\ 0\\.033054476556844396\ \(0\)\
\-\ extent\\:\\ 0\\.033054476556844396\ \(0\)\
\-\ has\\:\\ 0\\.03299513301122437\ \(0\)\
\-\ for\\:\\ 0\\.0328410995891153\ \(0\)\
\-\ uncommon\\:\\ 0\\.0326819213556394\ \(0\)\
\-\ smaller\\:\\ 0\\.03250355430008484\ \(0\)\
\-\ region\\:\\ 0\\.03240606864381283\ \(0\)\
\-\ prognosis\\:\\ 0\\.03178390762397148\ \(0\)\
\-\ physician\\:\\ 0\\.03168010838540088\ \(0\)\
\-\ tubular\\:\\ 0\\.031378546070884916\ \(0\)\
\-\ t2\\:\\ 0\\.031169365827243136\ \(0\)\
\-\ 65\\:\\ 0\\.030905818258205327\ \(0\)\
\-\ reaction\\:\\ 0\\.03072618601896227\ \(0\)\
\-\ thickened\\:\\ 0\\.030465946166328035\ \(0\)\
\-\ poor\\:\\ 0\\.030465946166328035\ \(0\)\
\-\ represent\\:\\ 0\\.030054657987147557\ \(0\)\
\-\ their\\:\\ 0\\.029975511809737298\ \(0\)\
\-\ development\\:\\ 0\\.02985861719576842\ \(0\)\
\-\ smooth\\:\\ 0\\.029820127036214405\ \(0\)\
\-\ extends\\:\\ 0\\.029743841634521186\ \(0\)\
\-\ foci\\:\\ 0\\.029520349782817677\ \(0\)\
\-\ external\\:\\ 0\\.029199241506842093\ \(0\)\
\-\ bones\\:\\ 0\\.029061592352053075\ \(0\)\
\-\ caused\\:\\ 0\\.028960284402811506\ \(0\)\
\-\ around\\:\\ 0\\.02882768035725199\ \(0\)\
\-\ done\\:\\ 0\\.028730018599731125\ \(0\)\
\-\ arising\\:\\ 0\\.0286977965874511\ \(0\)\
\-\ without\\:\\ 0\\.028576185957711442\ \(0\)\
\-\ many\\:\\ 0\\.028476720353107277\ \(0\)\
\-\ appear\\:\\ 0\\.028445758864770892\ \(0\)\
\-\ initially\\:\\ 0\\.028323405071921156\ \(0\)\
\-\ most\\:\\ 0\\.028195208644315274\ \(0\)\
\-\ thin\\:\\ 0\\.028114815468539667\ \(0\)\
\-\ evaluate\\:\\ 0\\.02808557009669245\ \(0\)\
\-\ irregular\\:\\ 0\\.027884549665459286\ \(0\)\
\-\ mri\\:\\ 0\\.027809523908464858\ \(0\)\
\-\ pattern\\:\\ 0\\.026965313546325684\ \(0\)\
\-\ femoral\\:\\ 0\\.02684424653566675\ \(0\)\
\-\ commonly\\:\\ 0\\.02672545108564123\ \(0\)\
\-\ its\\:\\ 0\\.02672545108564123\ \(0\)\
\-\ juxtaposed\\:\\ 0\\.02668575686022926\ \(0\)\
\-\ surgical\\:\\ 0\\.026331655974365806\ \(0\)\
\-\ well\\:\\ 0\\.026232637691300173\ \(0\)\
\-\ involvement\\:\\ 0\\.026141271406607335\ \(0\)\
\-\ reported\\:\\ 0\\.026013784983979108\ \(0\)\
\-\ knee\\:\\ 0\\.02588881490576351\ \(0\)\
\-\ peripheral\\:\\ 0\\.025827242831423083\ \(0\)\
\-\ defined\\:\\ 0\\.025766263755774305\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.025646039667535314\ \(0\)\
\-\ juxtacortical\\:\\ 0\\.025402133039272905\ \(0\)\
\-\ palpable\\:\\ 0\\.0253740881597736\ \(0\)\
\-\ because\\:\\ 0\\.02524237083247728\ \(0\)\
\-\ presentation\\:\\ 0\\.024862902519870844\ \(0\)\
\-\ masses\\:\\ 0\\.024588318062526104\ \(0\)\
\-\ undetected\\:\\ 0\\.024491387444456673\ \(0\)\
\-\ followed\\:\\ 0\\.02438992235120286\ \(0\)\
\-\ swelling\\:\\ 0\\.024309057755905916\ \(0\)\
\-\ cases\\:\\ 0\\.024293008034389222\ \(0\)\
\-\ central\\:\\ 0\\.024119095155415136\ \(0\)\
\-\ plain\\:\\ 0\\.023829512501479754\ \(0\)\
\-\ emanating\\:\\ 0\\.023784958278957907\ \(0\)\
\-\ no\\:\\ 0\\.023490206348163015\ \(0\)\
\-\ adjacent\\:\\ 0\\.02341157528885888\ \(0\)\
\-\ mr\\:\\ 0\\.02336987407281696\ \(0\)\
\-\ such\\:\\ 0\\.02323282084845009\ \(0\)\
\-\ heterogenously\\:\\ 0\\.023207763623500317\ \(0\)\
\-\ approximately\\:\\ 0\\.023045797621891472\ \(0\)\
\-\ show\\:\\ 0\\.02292842143718842\ \(0\)\
\-\ clinical\\:\\ 0\\.02288977465343066\ \(0\)\
\-\ correlating\\:\\ 0\\.022719752495820002\ \(0\)\
\-\ fat\\:\\ 0\\.022467510763162793\ \(0\)\
\-\ normal\\:\\ 0\\.022119993865704297\ \(0\)\
\-\ when\\:\\ 0\\.021817251486904603\ \(0\)\
\-\ trauma\\:\\ 0\\.020975849533876132\ \(0\)\
\-\ due\\:\\ 0\\.020761198071010043\ \(0\)\
\-\ lesions\\:\\ 0\\.020742872119727314\ \(0\)\
\-\ enzymes\\:\\ 0\\.020640515981587605\ \(0\)\
\-\ favorable\\:\\ 0\\.020640515981587605\ \(0\)\
\-\ are\\:\\ 0\\.020557603490254275\ \(0\)\
\-\ these\\:\\ 0\\.02039572565044945\ \(0\)\
\-\ patients\\:\\ 0\\.020318247449511138\ \(0\)\
\-\ more\\:\\ 0\\.019832544703029933\ \(0\)\
\-\ intramedullary\\:\\ 0\\.01981895391454865\ \(0\)\
\-\ popliteal\\:\\ 0\\.01947637071264654\ \(0\)\
\-\ mentioned\\:\\ 0\\.01909448592033491\ \(0\)\
\-\ panel\\:\\ 0\\.018953760269277913\ \(0\)\
\-\ other\\:\\ 0\\.018756562332388753\ \(0\)\
\-\ usual\\:\\ 0\\.018753748131410744\ \(0\)\
\-\ this\\:\\ 0\\.01861609862056\ \(0\)\
\-\ extremely\\:\\ 0\\.018505322230302726\ \(0\)\
\-\ it\\:\\ 0\\.018488205803821593\ \(0\)\
\-\ right\\:\\ 0\\.017961826203071414\ \(0\)\
\-\ findings\\:\\ 0\\.017825591474751608\ \(0\)\
\-\ survival\\:\\ 0\\.017624584498776057\ \(0\)\
\-\ diaphysis\\:\\ 0\\.017579678697997786\ \(0\)\
\-\ contrast\\:\\ 0\\.01754890993767544\ \(0\)\
\-\ after\\:\\ 0\\.017521345193451193\ \(0\)\
\-\ treatment\\:\\ 0\\.017204832798338413\ \(0\)\
\-\ better\\:\\ 0\\.017047389843318467\ \(0\)\
\-\ heterogenous\\:\\ 0\\.01700992424778382\ \(0\)\
\-\ factor\\:\\ 0\\.01693629753693306\ \(0\)\
\-\ surgically\\:\\ 0\\.01675939085350532\ \(0\)\
\-\ images\\:\\ 0\\.01670689504950313\ \(0\)\
\-\ develop\\:\\ 0\\.01662465537618255\ \(0\)\
\-\ frequent\\:\\ 0\\.016559378715638153\ \(0\)\
\-\ resected\\:\\ 0\\.016527238278422198\ \(0\)\
\-\ earlier\\:\\ 0\\.016495420866141374\ \(0\)\
\-\ firm\\:\\ 0\\.016371255702057715\ \(0\)\
\-\ metabolic\\:\\ 0\\.016371255702057715\ \(0\)\
\-\ center\\:\\ 0\\.0163409606778197\ \(0\)\
\-\ variant\\:\\ 0\\.016025551942116825\ \(0\)\
\-\ visible\\:\\ 0\\.01591822621068378\ \(0\)\
\-\ vessel\\:\\ 0\\.01584005419270044\ \(0\)\
\-\ major\\:\\ 0\\.01578899170064261\ \(0\)\
\-\ period\\:\\ 0\\.01578899170064261\ \(0\)\
\-\ that\\:\\ 0\\.01567377818432251\ \(0\)\
\-\ incidence\\:\\ 0\\.01554534798454366\ \(0\)\
\-\ factors\\:\\ 0\\.015275754894681796\ \(0\)\
\-\ cbc\\:\\ 0\\.01506740302074651\ \(0\)\
\-\ gadolinium\\:\\ 0\\.015047302598465965\ \(0\)\
\-\ do\\:\\ 0\\.014968153329086065\ \(0\)\
\-\ recurrence\\:\\ 0\\.014910063518107202\ \(0\)\
\-\ another\\:\\ 0\\.014778527440626223\ \(0\)\
\-\ site\\:\\ 0\\.014565021437732731\ \(0\)\
\-\ progressive\\:\\ 0\\.013831182526344238\ \(0\)\
\-\ necrosis\\:\\ 0\\.013804008060145003\ \(0\)\
\-\ history\\:\\ 0\\.013799097051690147\ \(0\)\
\-\ ct\\:\\ 0\\.013750392105772688\ \(0\)\
\-\ rate\\:\\ 0\\.013684529508129711\ \(0\)\
\-\ rare\\:\\ 0\\.013632841733455976\ \(0\)\
\-\ tender\\:\\ 0\\.013202106741784033\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.013070635703303668\ \(0\)\
\-\ presence\\:\\ 0\\.012975495812764573\ \(0\)\
\-\ pain\\:\\ 0\\.012924284172235968\ \(0\)\
\-\ 24\\:\\ 0\\.012803233482646207\ \(0\)\
\-\ liver\\:\\ 0\\.012457869821096795\ \(0\)\
\-\ study\\:\\ 0\\.012043990760781048\ \(0\)\
\-\ further\\:\\ 0\\.01176207012011328\ \(0\)\
\-\ radiograph\\:\\ 0\\.01176207012011328\ \(0\)\
\-\ patient\\:\\ 0\\.011747312775132732\ \(0\)\
\-\ aspect\\:\\ 0\\.011650488319196706\ \(0\)\
\-\ time\\:\\ 0\\.01070397052598383\ \(0\)\
\-\ been\\:\\ 0\\.010521324686562021\ \(0\)\
\-\ evidence\\:\\ 0\\.010250263567054557\ \(0\)\
\-\ than\\:\\ 0\\.01023708184416283\ \(0\)\
\-\ over\\:\\ 0\\.010041547128864778\ \(0\)\
\-\ post\\:\\ 0\\.009826428524251717\ \(0\)\
\-\ consistent\\:\\ 0\\.00979195479840271\ \(0\)\
\-\ can\\:\\ 0\\.009476743118868336\ \(0\)\
\-\ have\\:\\ 0\\.009021415401713603\ \(0\)\
\-\ lateral\\:\\ 0\\.008962239737225888\ \(0\)\
\-\ male\\:\\ 0\\.008040520800837144\ \(0\)\
\-\ was\\:\\ 0\\.00629370843622704\ \(0\)\
